{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:50:14Z","timestamp":1791633014512,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eprac.2026.09.006","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:29:49Z","timestamp":1789831789000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in Abdominal Adiposity and Associations with Metabolic Health Markers Following Tirzepatide in Japanese Participants with Obesity Disease: Results from the SURMOUNT-J Study"],"prefix":"10.1016","author":[{"given":"Hironori","family":"Waki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kaneyuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Shingaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Oura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nagakubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.eprac.2026.09.006_bib1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-8587(19)30084-1","article-title":"International Chair on Cardiometabolic Risk Working Group on Visceral Obesity. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement","volume":"7","author":"Neeland","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2026.09.006_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cld.1183","article-title":"Nonalcoholic fatty liver disease: the role of visceral adipose tissue","volume":"19","author":"Hanlon","year":"2022","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"18","key":"10.1016\/j.eprac.2026.09.006_bib3","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186420","article-title":"MASH: the nexus of metabolism, inflammation, and fibrosis","volume":"135","author":"Steinberg","year":"2025","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.eprac.2026.09.006_bib4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.metabol.2009.03.021","article-title":"ERA JUMP study group. Higher liver fat content among Japanese in Japan compared with Non-Hispanic whites in the United States","volume":"58","author":"Azuma","year":"2009","journal-title":"Metabolism"},{"issue":"Suppl_1","key":"10.1016\/j.eprac.2026.09.006_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1467-789X.2007.00439.x","article-title":"Obesity in Asia Collaboration. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension","volume":"9","author":"Huxley","year":"2008","journal-title":"Obes Rev"},{"issue":"7","key":"10.1016\/j.eprac.2026.09.006_bib6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/sj.ijo.0803248","article-title":"Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study","volume":"30","author":"Kadowaki","year":"2006","journal-title":"Int J Obes (Lond)"},{"issue":"4","key":"10.1016\/j.eprac.2026.09.006_bib7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3945\/ajcn.112.035758","volume":"96","author":"Nazare","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"9","key":"10.1016\/j.eprac.2026.09.006_bib8","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2337\/dc07-0218","article-title":"Reduction of visceral fat is associated with decrease in the number of metabolic risk factors in Japanese men","volume":"30","author":"Okauchi","year":"2007","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.006_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013831","article-title":"Risk for metabolic diseases in normal weight individuals with visceral fat accumulation: a cross-sectional study in Japan","volume":"7","author":"Tatsumi","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.eprac.2026.09.006_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1507\/endocrj.EJ23-0593","article-title":"Creation Committee for Guidelines for the Management of Obesity Disease 2022 by Japan Society for the Study of Obesity (JASSO). Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan","volume":"71","author":"Ogawa","year":"2024","journal-title":"Endocr J"},{"issue":"5","key":"10.1016\/j.eprac.2026.09.006_bib11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S2213-8587(24)00377-2","article-title":"Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"13","author":"Kadowaki","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2026.09.006_bib12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/jdi.13306","article-title":"Japanese Clinical Practice Guideline for Diabetes 2019","volume":"11","author":"Araki","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"2","key":"10.1016\/j.eprac.2026.09.006_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.eprac.2026.09.006_bib14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.eprac.2026.09.006_bib15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hep4.1841","article-title":"Fibrosis-4 index as an independent predictor of mortality and liver-related outcomes in NAFLD","volume":"6","author":"Vieira Barbosa","year":"2022","journal-title":"Hepatol Commun"},{"issue":"12","key":"10.1016\/j.eprac.2026.09.006_bib16","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","article-title":"Correct homeostasis model assessment (HOMA) evaluation uses the computer program","volume":"21","author":"Levy","year":"1998","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2026.09.006_bib17","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41577-024-01103-8","article-title":"Adipokines: masterminds of metabolic inflammation","volume":"25","author":"Tilg","year":"2025","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.eprac.2026.09.006_bib18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2026.09.006_bib19","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.2337\/dc25-0763","article-title":"Tirzepatide treatment and associated changes in \u03b2-cell function and insulin sensitivity in people with obesity or overweight with prediabetes or normoglycemia: a post hoc analysis from the SURMOUNT-1 trial","volume":"48","author":"Mari","year":"2025","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2026.09.006_bib20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s13300-025-01704-z","article-title":"Insulin sensitivity and beta-cell function following tirzepatide in Japanese patients with type 2 diabetes: a SURPASS J-mono analysis","volume":"16","author":"Hamamoto","year":"2025","journal-title":"Diabetes Ther"},{"issue":"6","key":"10.1016\/j.eprac.2026.09.006_bib21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2026.09.006_bib22","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad056","article-title":"Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1)","volume":"7","author":"Lee","year":"2023","journal-title":"J Endocr Soc"},{"issue":"2","key":"10.1016\/j.eprac.2026.09.006_bib23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.006_bib24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12916-025-03891-9","article-title":"Visceral adipose tissue area and proportion provide distinct reflections of cardiometabolic outcomes in weight loss; pooled analysis of MRI-assessed CENTRAL and DIRECT PLUS dietary randomized controlled trials","volume":"23","author":"Klein","year":"2025","journal-title":"BMC Med"},{"issue":"12","key":"10.1016\/j.eprac.2026.09.006_bib25","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jcmg.2014.07.017","article-title":"Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA Study","volume":"7","author":"Shah","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.eprac.2026.09.006_bib26","article-title":"Rethinking obesity through the lens of lipid spillover","volume":"11","author":"Khanna","year":"2026","journal-title":"JACC Basic Transl Sci"},{"issue":"6","key":"10.1016\/j.eprac.2026.09.006_bib27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2026.09.006_bib28","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.eprac.2026.09.006_bib29","doi-asserted-by":"crossref","DOI":"10.5888\/pcd17.200112","article-title":"Discriminatory capacity of anthropometric indices for cardiovascular disease in adults: a systematic review and meta-analysis","volume":"17","author":"Darbandi","year":"2020","journal-title":"Prev Chronic Dis"},{"issue":"7","key":"10.1016\/j.eprac.2026.09.006_bib30","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/eurheartj\/ehm026","article-title":"Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies","volume":"28","author":"de Koning","year":"2007","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.eprac.2026.09.006_bib31","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.2337\/dc13-0219","article-title":"The importance of waist circumference and BMI for mortality risk in diabetic adults","volume":"36","author":"Katzmarzyk","year":"2013","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2026.09.006_bib32","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12603-018-1042-4","article-title":"Effect of body weight, waist circumference and their changes on mortality: a 10-year population-based study","volume":"22","author":"Lee","year":"2018","journal-title":"J Nutr Health Aging"},{"issue":"10","key":"10.1016\/j.eprac.2026.09.006_bib33","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/oby.22942","article-title":"Waist circumference change during intensive lifestyle intervention and cardiovascular morbidity and mortality in the Look AHEAD trial","volume":"28","author":"Olson","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1016\/j.eprac.2026.09.006_bib34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41574-019-0310-7","article-title":"Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity","volume":"16","author":"Ross","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2026.09.006_bib35","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1111\/dom.70884","volume":"28","author":"Wachiraphansakul","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.eprac.2026.09.006_bib36","doi-asserted-by":"crossref","first-page":"7689","DOI":"10.1111\/dom.70957","article-title":"Comparative effects of antidiabetic drugs on body composition: a systematic review and network meta-analysis","volume":"28","author":"Rakhsha","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.09.006_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2026.113286","article-title":"Early changes in body composition with tirzepatide in adults with obesity: a real-world BIA study","volume":"150","author":"Angelopoulos","year":"2026","journal-title":"Nutrition"},{"issue":"5","key":"10.1016\/j.eprac.2026.09.006_bib38","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.006_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70155","article-title":"Muscle health in the modern era of incretin-based therapies","volume":"56","author":"de Girolamo","year":"2026","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.eprac.2026.09.006_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.eurger.2014.04.003","article-title":"Ethnic and geographic variations in muscle mass, muscle strength and physical performance measures","volume":"5","author":"Woo","year":"2014","journal-title":"Eur Geriatr Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26011481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26011481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:33:40Z","timestamp":1791632020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26011481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S1530891X26011481"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.09.006","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in Abdominal Adiposity and Associations with Metabolic Health Markers Following Tirzepatide in Japanese Participants with Obesity Disease: Results from the SURMOUNT-J Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}